We are live on ! Find out more
JJ

Johnson & Johnson Portfolio holdings

AUM $799M Turnover 17.65%
1-Year Est. Return 253.51%
This Fund
S&P 500
This Quarter Est. Return
+20.06%
1 Year Est. Return
+253.51%
3 Year Est. Return
+280.64%
5 Year Est. Return
+320.83%
10 Year Est. Return
–
AUM
$652M
AUM Growth
+$97.3M
Cap. Flow
-$3.95M
Cap. Flow %
-0.61%
Top 10 Hldgs %
98.99%
Holding
17
New
–
Increased
–
Reduced
2
Closed
1
Avg Time Held
3.5 years
Top 10 Avg Time Held
2.8 years
Top 20 Avg Time Held
3.5 years

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
RLYB icon
Rallybio
RLYB
+$2.06M
2
LYEL icon
Lyell Immunopharma
LYEL
+$1.69M
3
NNOX icon
Nano X Imaging
NNOX
+$198K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PTGX icon
1
Protagonist Therapeutics
PTGX
$8.82B
$258M 39.57%
2,449,183
– –
2021 Q3
18 quarters
NBTX icon
2
Nanobiotix
NBTX
$1.08B
$174M 26.61%
5,623,816
– –
2023 Q3
10 quarters
MGTX icon
3
MeiraGTx Holdings
MGTX
$904M
$57.5M 8.82%
6,641,064
– –
2021 Q3
18 quarters
RAPP icon
4
Rapport Therapeutics
RAPP
$1.36B
$55.8M 8.56%
1,784,517
– –
2024 Q2
7 quarters
CVRX icon
5
CVRx
CVRX
$35.7M
$38.1M 5.84%
4,024,861
– –
2021 Q3
18 quarters
CTNM icon
6
Contineum Therapeutics
CTNM
$306M
$25.8M 3.96%
1,979,173
– –
2024 Q2
7 quarters
LEGN icon
7
Legend Biotech
LEGN
$3.7B
$14.7M 2.26%
814,586
– –
2021 Q3
18 quarters
XNCR icon
8
Xencor
XNCR
$1.74B
$9.02M 1.38%
748,062
– –
2021 Q4
17 quarters
PRCT icon
9
Procept Biorobotics
PRCT
$1B
$8.95M 1.37%
357,939
– –
2021 Q3
18 quarters
FATE icon
10
Fate Therapeutics
FATE
$232M
$4.05M 0.62%
3,379,064
– –
2021 Q3
18 quarters
NMRA icon
11
Neumora Therapeutics
NMRA
$66.6M
$3.61M 0.55%
1,849,445
– –
2023 Q3
10 quarters
RLYB icon
12
Rallybio
RLYB
$89.8M
$1.37M 0.21%
152,901
-301,644
-66% -$2.06M
2024 Q2
7 quarters
VOR icon
13
Vor Biopharma
VOR
$1.11B
$959K 0.15%
53,732
– –
2021 Q3
18 quarters
LAB icon
14
Standard BioTools
LAB
$248M
$287K 0.04%
311,967
– –
2024 Q1
8 quarters
NNOX icon
15
Nano X Imaging
NNOX
$40.1M
$190K 0.03%
83,554
-75,298
-47% -$198K
2021 Q4
17 quarters
ACET icon
16
Adicet Bio
ACET
$45.8M
$155K 0.02%
22,779
– –
2021 Q3
18 quarters
LYEL icon
17
Lyell Immunopharma
LYEL
$196M
– –
-54,887
Closed -$1.69M –

Similar funds

SEM
Suncoast Equity Management Tampa, Florida $798M AUM 14.62% 1-Year Est. Return
TI
TrueMark Investments Chicago, Illinois $798M AUM 25.52% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $798M AUM 18.61% 1-Year Est. Return
QCMNJ
Quantum Capital Management (New Jersey) Northfield, New Jersey $798M AUM 8.86% 1-Year Est. Return
LOPW
Live Oak Private Wealth Wilmington, North Carolina $800M AUM 24.59% 1-Year Est. Return
HW
HORAN Wealth Cincinnati, Ohio $800M AUM 23.65% 1-Year Est. Return
CCM
Corsair Capital Management New York $800M AUM 94.38% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 22.73% 1-Year Est. Return

Johnson & Johnson's Q1 2026 Portfolio in Review

As of Q1 2026, Johnson & Johnson held 17 positions worth $652M, up 18% from $555M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Johnson & Johnson's Q1 2026 filing shows 2 reduced and 1 closed positions. The largest sale was Rallybio, an estimated $2.06M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Johnson & Johnson's biggest Q1 2026 reduction was Rallybio, cutting an estimated $2.06M.
  • Johnson & Johnson fully exited Lyell Immunopharma in Q1 2026, selling an estimated $1.69M.
  • Johnson & Johnson's ten largest holdings make up 99% of its $652M portfolio in Q1 2026.
  • Johnson & Johnson opened 0 new positions and closed 1 in Q1 2026.
  • Johnson & Johnson's portfolio value rose 18% quarter-over-quarter to $652M.

Based on Johnson & Johnson's 13F filing for Q1 2026, filed 13 May 2026.